PMC:7376974 / 92958-93309 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T442","span":{"begin":171,"end":175},"obj":"Body_part"},{"id":"T443","span":{"begin":179,"end":183},"obj":"Body_part"}],"attributes":[{"id":"A442","pred":"fma_id","subj":"T442","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A443","pred":"fma_id","subj":"T443","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1659","span":{"begin":260,"end":264},"obj":"Species"},{"id":"1660","span":{"begin":273,"end":278},"obj":"Species"},{"id":"1661","span":{"begin":79,"end":92},"obj":"Chemical"}],"attributes":[{"id":"A1659","pred":"tao:has_database_id","subj":"1659","obj":"Tax:10090"},{"id":"A1660","pred":"tao:has_database_id","subj":"1660","obj":"Tax:10298"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T854","span":{"begin":7,"end":9},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T855","span":{"begin":111,"end":119},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T856","span":{"begin":171,"end":175},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T857","span":{"begin":179,"end":183},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T858","span":{"begin":184,"end":189},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7076","span":{"begin":84,"end":92},"obj":"Chemical"},{"id":"T89486","span":{"begin":111,"end":119},"obj":"Chemical"},{"id":"T84988","span":{"begin":123,"end":131},"obj":"Chemical"}],"attributes":[{"id":"A7856","pred":"chebi_id","subj":"T7076","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A30625","pred":"chebi_id","subj":"T89486","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A31743","pred":"chebi_id","subj":"T84988","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}

{"project":"LitCovid-sentences","denotations":[{"id":"T558","span":{"begin":0,"end":45},"obj":"Sentence"},{"id":"T559","span":{"begin":46,"end":51},"obj":"Sentence"},{"id":"T560","span":{"begin":52,"end":132},"obj":"Sentence"},{"id":"T561","span":{"begin":133,"end":143},"obj":"Sentence"},{"id":"T562","span":{"begin":144,"end":206},"obj":"Sentence"},{"id":"T563","span":{"begin":207,"end":220},"obj":"Sentence"},{"id":"T564","span":{"begin":221,"end":279},"obj":"Sentence"},{"id":"T565","span":{"begin":280,"end":322},"obj":"Sentence"},{"id":"T566","span":{"begin":323,"end":351},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}

{"project":"2_test","denotations":[{"id":"32667191-30594660-153410","span":{"begin":317,"end":320},"obj":"30594660"}],"text":"Figure 18 Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpGm adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread in vitro. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (153). Copyright 2019 Elsevier B.V."}